PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Drug or technology

LY4064809

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 3 TRIAL

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

ClinicalTrials.gov

This is a Phase 3 RCT registration with no results posted; the study is actively recruiting and designed to test a novel PIK3CA inhibitor in advanced breast cancer, but outcome data are not yet available.

PreliminaryEli Lilly and Company LY4064809 Ribociclib

Reported

Planned sample size800

Study phasePhase 3

Primary outcome measure (Part 1)Overall Response Rate (ORR): Percentage of…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support